NORD: SHARE CAPITAL INCREASE REGISTERED

22 december 2009 Reference is made to the stock exchange notice dated 18 December 2009 regarding the resolution made by the shareholders of NorDiag ASA (?NorDiag? or the ?Company?), in an extraordinary general meeting held on 18 December 2009, to increase the share capital of the Company following a private placement. The share capital increase of NOK 42,000,000 has now been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). As a consequence, the new registered share capital of NorDiag is NOK 54,065,282, divided into 54,065,282 shares, each with a par value of NOK 1.00. The new shares in NorDiag are registered in the Norwegian Central Securities Depository (VPS) and are listed on Oslo Børs today. Contact:     CFO Tone Kvåle        Phone: +47 915 19576 About NorDiag: NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and tests) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and is the fastest growing field within diagnostics. The company?s sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 40.1 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD. For further information, please see www.nordiag.com. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act) [HUG#1366428]